Public disclosures

Polsky Bruce

Company insiders · Director · Atea Pharmaceuticals, Inc.

Advertisement
FollowLatest SEC filingSEC filer historyProfile details as reported on 2026-11-19.Following & alerts
Reported transaction lines
10
Buy lines
0
Sell lines
4

Filing activity by month

Original filing lines in up to 12 months with activity.

  • 2026-1110

Frequently disclosed stocks

Disclosure history

More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSource
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 149830 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.04. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-192026-11-19

≈ $35,298.38

8,750 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 0 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-182026-11-18

18,252 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 18252 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-18

8,720 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Stock Option (Right to Buy) · Derivative security · Direct ownership · Reported balance after transaction: 26972 · The option is fully vested and exercisable. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-162026-11-18

48,028 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $3.91 to $4.00. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-182026-11-18

≈ $72,099.05

18,252 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 176832 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-182026-11-18

18,252 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.00 to $4.10. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-18

≈ $35,155.55

8,720 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 167300 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-172026-11-18

8,720 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Sell
Filing details

SEC transaction code S

Common Stock · Direct ownership · Reported balance after transaction: 158580 · SEC code covers open-market or private transactions · The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $4.20 to $4.33. The reporting person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer full information regarding the number of shares sold at each separate price within the range set forth in this footnote. · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-162026-11-18

≈ $60,840.35

14,254 shares/units

SEC 4
Polsky Bruce

Director · Atea Pharmaceuticals, Inc.

AVIR

Atea Pharmaceuticals, Inc.

Exercise or conversion
Filing details

SEC transaction code M

Common Stock · Direct ownership · Reported balance after transaction: 172834 · All sale transactions reported herein were executed to pay the exercise price of the options and for the Reporting Person's tax planning purposes.

2026-11-162026-11-18

48,028 shares/units

SEC 4

Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.

Advertisement